Published in Cancer Res on August 01, 2002
Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene (2009) 8.01
Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol (2005) 6.44
HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer (2011) 6.32
The genetic basis of kidney cancer: a metabolic disease. Nat Rev Urol (2010) 5.04
Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth. Proc Natl Acad Sci U S A (2008) 4.79
Regulation of the chemokine receptor CXCR4 by hypoxia. J Exp Med (2003) 3.71
Regulation of HIF-1alpha stability through S-nitrosylation. Mol Cell (2007) 3.50
The biology of hypoxia: the role of oxygen sensing in development, normal function, and disease. Genes Dev (2004) 2.77
Vascular endothelial growth factor in eye disease. Prog Retin Eye Res (2008) 2.73
A molecule targeting VHL-deficient renal cell carcinoma that induces autophagy. Cancer Cell (2008) 2.38
Development of HIF-1 inhibitors for cancer therapy. J Cell Mol Med (2009) 2.09
Small-molecule modulators of p53 family signaling and antitumor effects in p53-deficient human colon tumor xenografts. Proc Natl Acad Sci U S A (2006) 1.80
Prolyl hydroxylase inhibitors increase neoangiogenesis and callus formation following femur fracture in mice. J Orthop Res (2009) 1.76
Hypoxic induction of an HIF-1alpha-dependent bFGF autocrine loop drives angiogenesis in human endothelial cells. Blood (2005) 1.74
S100A4-induced cell motility and metastasis is restricted by the Wnt/β-catenin pathway inhibitor calcimycin in colon cancer cells. Mol Biol Cell (2011) 1.71
Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition. Mol Cancer Ther (2009) 1.67
Inhibitory Effect of the Noncamptothecin Topoisomerase I Inhibitor LMP-400 on Female Mice Models and Human Pheochromocytoma Cells. Endocrinology (2015) 1.42
The tumour suppressor C/EBPδ inhibits FBXW7 expression and promotes mammary tumour metastasis. EMBO J (2010) 1.41
Hypoxia--a key regulator of angiogenesis and inflammation in rheumatoid arthritis. Nat Rev Rheumatol (2012) 1.41
HIF-1α pathway: role, regulation and intervention for cancer therapy. Acta Pharm Sin B (2015) 1.40
Cancer-stromal cell interactions mediated by hypoxia-inducible factors promote angiogenesis, lymphangiogenesis, and metastasis. Oncogene (2012) 1.37
Targeting cancer cells through autophagy for anticancer therapy. Curr Opin Cell Biol (2010) 1.34
Natural product-based inhibitors of hypoxia-inducible factor-1 (HIF-1). Curr Drug Targets (2006) 1.33
Absence of the Birt-Hogg-Dubé gene product is associated with increased hypoxia-inducible factor transcriptional activity and a loss of metabolic flexibility. Oncogene (2010) 1.33
A chemical genomics screen highlights the essential role of mitochondria in HIF-1 regulation. Proc Natl Acad Sci U S A (2008) 1.33
Identification of a novel small molecule HIF-1alpha translation inhibitor. Clin Cancer Res (2009) 1.33
Metabolic control of the Treg/Th17 axis. Immunol Rev (2013) 1.26
Multihistology, target-driven pilot trial of oral topotecan as an inhibitor of hypoxia-inducible factor-1α in advanced solid tumors. Clin Cancer Res (2011) 1.22
Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies. Drug Resist Updat (2009) 1.20
Methylalpinumisoflavone inhibits hypoxia-inducible factor-1 (HIF-1) activation by simultaneously targeting multiple pathways. J Biol Chem (2008) 1.19
Hypoxia in models of lung cancer: implications for targeted therapeutics. Clin Cancer Res (2010) 1.19
Saururus cernuus lignans--potent small molecule inhibitors of hypoxia-inducible factor-1. Biochem Biophys Res Commun (2005) 1.18
JNK1 mediates degradation HIF-1alpha by a VHL-independent mechanism that involves the chaperones Hsp90/Hsp70. Cancer Res (2010) 1.18
Drugging the undruggable: transcription therapy for cancer. Biochim Biophys Acta (2012) 1.14
PX-478, an inhibitor of hypoxia-inducible factor-1alpha, enhances radiosensitivity of prostate carcinoma cells. Int J Cancer (2008) 1.12
Targeting the metabolic microenvironment of tumors. Adv Pharmacol (2012) 1.11
Laurenditerpenol, a new diterpene from the tropical marine alga Laurenciaintricata that potently inhibits HIF-1 mediated hypoxic signaling in breast tumor cells. J Nat Prod (2004) 1.11
The tumor suppressor folliculin regulates AMPK-dependent metabolic transformation. J Clin Invest (2014) 1.10
Real-time imaging of HIF-1alpha stabilization and degradation. PLoS One (2009) 1.09
HIF-1α inhibition by siRNA or chetomin in human malignant glioma cells: effects on hypoxic radioresistance and monitoring via CA9 expression. BMC Cancer (2010) 1.08
Marine Natural Products as Inhibitors of Hypoxic Signaling in Tumors. Phytochem Rev (2009) 1.08
A therapeutic role for targeting c-Myc/Hif-1-dependent signaling pathways. Cell Cycle (2010) 1.07
Virus-based reporter systems for monitoring transcriptional activity of hypoxia-inducible factor 1. Gene (2005) 1.07
Aminoflavone, a ligand of the aryl hydrocarbon receptor, inhibits HIF-1alpha expression in an AhR-independent fashion. Cancer Res (2010) 1.07
Identification of small molecule lead compounds for visceral leishmaniasis using a novel ex vivo splenic explant model system. PLoS Negl Trop Dis (2011) 1.07
HIF-1alpha: a valid therapeutic target for tumor therapy. Cancer Res Treat (2004) 1.06
Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma. Cancer Biol Ther (2009) 1.04
Small-molecule inhibitors of the Rce1p CaaX protease. J Biomol Screen (2007) 1.03
Anti-angiogenic effects of SN38 (active metabolite of irinotecan): inhibition of hypoxia-inducible factor 1 alpha (HIF-1alpha)/vascular endothelial growth factor (VEGF) expression of glioma and growth of endothelial cells. J Cancer Res Clin Oncol (2004) 1.03
Hypoxia-inducible factor-1 (HIF-1): a potential target for intervention in ocular neovascular diseases. Curr Drug Targets (2013) 1.01
Effects of hypoxia on human cancer cell line chemosensitivity. BMC Cancer (2013) 1.00
New developments in radiation therapy for head and neck cancer: intensity-modulated radiation therapy and hypoxia targeting. Semin Oncol (2008) 0.98
Chemotherapy-mediated p53-dependent DNA damage response in clear cell renal cell carcinoma: role of the mTORC1/2 and hypoxia-inducible factor pathways. Cell Death Dis (2013) 0.96
Investigating the correlations among the chemical structures, bioactivity profiles and molecular targets of small molecules. Bioinformatics (2010) 0.94
Absence of GAPDH regulation in tumor-cells of different origin under hypoxic conditions in - vitro. BMC Res Notes (2009) 0.94
In vivo and in vitro effects of a HIF-1alpha inhibitor, RX-0047. J Cell Biochem (2008) 0.93
Flavopiridol downregulates hypoxia-mediated hypoxia-inducible factor-1alpha expression in human glioma cells by a proteasome-independent pathway: implications for in vivo therapy. Neuro Oncol (2005) 0.93
A cyclic peptide inhibitor of HIF-1 heterodimerization that inhibits hypoxia signaling in cancer cells. J Am Chem Soc (2013) 0.92
Therapeutic vulnerability of an in vivo model of alveolar soft part sarcoma (ASPS) to antiangiogenic therapy. J Pediatr Hematol Oncol (2009) 0.92
In vivo topoisomerase I inhibition attenuates the expression of hypoxia-inducible factor 1α target genes and decreases tumor angiogenesis. Mol Med (2012) 0.92
The role of hypoxia-inducible factor-2 in digestive system cancers. Cell Death Dis (2015) 0.92
The Siah2-HIF-FoxA2 axis in prostate cancer – new markers and therapeutic opportunities. Oncotarget (2010) 0.91
Identification of small molecule compounds that inhibit the HIF-1 signaling pathway. Mol Cancer (2009) 0.91
Potent and sustained inhibition of HIF-1α and downstream genes by a polyethyleneglycol-SN38 conjugate, EZN-2208, results in anti-angiogenic effects. Angiogenesis (2011) 0.91
NGF activation of TrkA induces vascular endothelial growth factor expression via induction of hypoxia-inducible factor-1α. Mol Cell Neurosci (2010) 0.91
Prodeath or prosurvival: two facets of hypoxia inducible factor-1 in perinatal brain injury. Exp Neurol (2008) 0.91
[Retroviral reporter systems for the assessment of activity of stress-induced signal transduction pathways controlled by p53, HIF-1 and HSF-1 transcription factors]. Mol Biol (Mosk) (2005) 0.90
GAPDH is not regulated in human glioblastoma under hypoxic conditions. BMC Mol Biol (2007) 0.89
Small-molecule proteomimetic inhibitors of the HIF-1α-p300 protein-protein interaction. Chembiochem (2014) 0.89
Autocrine production of IL-11 mediates tumorigenicity in hypoxic cancer cells. J Clin Invest (2013) 0.89
Single-antibody, targeted nanoparticle delivery of camptothecin. Mol Pharm (2013) 0.89
Differential regulation of human PlGF gene expression in trophoblast and nontrophoblast cells by oxygen tension. Placenta (2009) 0.89
Inhibition of hypoxia-inducible factor-1alpha (HIF-1alpha) protein synthesis by DNA damage inducing agents. PLoS One (2010) 0.89
HIF-1alpha modulation by topoisomerase inhibitors in non-small cell lung cancer cell lines. J Cancer Res Clin Oncol (2009) 0.88
Isolation of hypoxia-inducible factor 1 (HIF-1) inhibitors from frankincense using a molecularly imprinted polymer. Invest New Drugs (2010) 0.86
Perspectives on biologically active camptothecin derivatives. Med Res Rev (2015) 0.85
Cell cycle regulation to repair the infarcted myocardium. Heart Fail Rev (2003) 0.84
Transferable neuronal mini-cultures to accelerate screening in primary and induced pluripotent stem cell-derived neurons. Sci Rep (2015) 0.83
Candidate biomarkers for cervical cancer treatment: Potential for clinical practice (Review). Mol Clin Oncol (2014) 0.82
Hypoxia-inducible factor-1 as a therapeutic target in endometrial cancer management. Obstet Gynecol Int (2010) 0.82
The role of topoisomerases and RNA transcription in the action of the antitumour benzonaphthyridine derivative SN 28049. Cancer Chemother Pharmacol (2008) 0.80
A synthetic manassantin a derivative inhibits hypoxia-inducible factor 1 and tumor growth. PLoS One (2014) 0.80
A novel inhibitor of hypoxia-inducible factor-1α P3155 also modulates PI3K pathway and inhibits growth of prostate cancer cells. BMC Cancer (2011) 0.80
Microregional antitumor activity of a small-molecule hypoxia-inducible factor 1 inhibitor. Int J Mol Med (2011) 0.80
Targeted therapy for the loss of von Hippel-Lindau in renal cell carcinoma: a novel molecule that induces autophagic cell death. Autophagy (2008) 0.80
NSC606985, a novel camptothecin analog, induces apoptosis and growth arrest in prostate tumor cells. Cancer Chemother Pharmacol (2008) 0.79
Protein kinase Cdelta stimulates proteasome-dependent degradation of C/EBPalpha during apoptosis induction of leukemic cells. PLoS One (2009) 0.79
Internal Ribosome Entry Site-Based Bicistronic In Situ Reporter Assays for Discovery of Transcription-Targeted Lead Compounds. Chem Biol (2015) 0.79
Ring-opening polymerization of prodrugs: a versatile approach to prepare well-defined drug-loaded nanoparticles. Angew Chem Int Ed Engl (2014) 0.79
Potent and selective chemical probe of hypoxic signalling downstream of HIF-α hydroxylation via VHL inhibition. Nat Commun (2016) 0.78
Silver nanoparticles inhibit the function of hypoxia-inducible factor-1 and target genes: insight into the cytotoxicity and antiangiogenesis. Int J Nanomedicine (2016) 0.78
Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: focus on the cancer hallmark of tumor angiogenesis. Carcinogenesis (2015) 0.78
GLUT1 as a Prognostic Factor for Classical Hodgkin's Lymphoma: Correlation with PD-L1 and PD-L2 Expression. J Pathol Transl Med (2017) 0.77
BACPTDP: a water-soluble camptothecin pro-drug with enhanced activity in hypoxic/acidic tumors. Cancer Chemother Pharmacol (2010) 0.77
Key pathways and genes controlling the development and progression of clear cell renal cell carcinoma (ccRCC) based on gene set enrichment analysis. Int Urol Nephrol (2013) 0.77
Deletion of HIF-1α partially rescues the abnormal hyaloid vascular system in Cited2 conditional knockout mouse eyes. Mol Vis (2012) 0.77
Pharmacological modulators of the circadian clock as potential therapeutic drugs. Mutat Res (2009) 0.76
Suppression of signal transducers and activators of transcription 1 in hepatocellular carcinoma is associated with tumor progression. Int J Cancer (2012) 0.76
DNA sequence selectivity of human topoisomerase I-mediated DNA cleavage induced by camptothecin. Protein Sci (2009) 0.75
Molecular and functional evaluation of a novel HIF inhibitor, benzopyranyl 1,2,3-triazole compound. Oncotarget (2017) 0.75
Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol (2006) 3.98
Transcript and protein expression profiles of the NCI-60 cancer cell panel: an integromic microarray study. Mol Cancer Ther (2007) 3.84
Regulation of the chemokine receptor CXCR4 by hypoxia. J Exp Med (2003) 3.71
Karyotypic complexity of the NCI-60 drug-screening panel. Cancer Res (2003) 3.42
Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel. Mol Cancer Ther (2006) 2.55
Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. Cancer Res (2005) 2.49
Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol (2005) 2.36
Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev Drug Discov (2003) 2.32
Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol Cancer Ther (2003) 2.24
Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo. Clin Cancer Res (2007) 2.22
Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood (2007) 2.15
Novel effect of antihelminthic Niclosamide on S100A4-mediated metastatic progression in colon cancer. J Natl Cancer Inst (2011) 2.11
Synthesis and biological evaluation of novel curcumin analogs as anti-cancer and anti-angiogenesis agents. Bioorg Med Chem (2004) 2.09
Development of HIF-1 inhibitors for cancer therapy. J Cell Mol Med (2009) 2.09
Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas. Cancer Res (2011) 2.08
Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck. Cancer Res (2005) 2.07
Integrating global gene expression and radiation survival parameters across the 60 cell lines of the National Cancer Institute Anticancer Drug Screen. Cancer Res (2008) 2.01
Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications. Cancer Res (2004) 1.96
PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer. J Clin Oncol (2013) 1.92
Identification of small molecule inhibitors of anthrax lethal factor. Nat Struct Mol Biol (2003) 1.86
Persistent activation of the Akt pathway in head and neck squamous cell carcinoma: a potential target for UCN-01. Clin Cancer Res (2004) 1.83
Hypoxic induction of an HIF-1alpha-dependent bFGF autocrine loop drives angiogenesis in human endothelial cells. Blood (2005) 1.74
A pharmacologic inhibitor of the protease Taspase1 effectively inhibits breast and brain tumor growth. Cancer Res (2011) 1.74
The metastasis-associated gene S100A4 is a novel target of beta-catenin/T-cell factor signaling in colon cancer. Gastroenterology (2006) 1.73
S100A4-induced cell motility and metastasis is restricted by the Wnt/β-catenin pathway inhibitor calcimycin in colon cancer cells. Mol Biol Cell (2011) 1.71
Schedule-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts. Cancer Res (2004) 1.70
Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition. Mol Cancer Ther (2009) 1.67
The TSC2/mTOR pathway drives endothelial cell transformation induced by the Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor. Cancer Cell (2006) 1.63
In vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative. Cancer Chemother Pharmacol (2005) 1.60
Subdural hematomas in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving imatinib mesylate in conjunction with systemic and intrathecal chemotherapy. Leuk Lymphoma (2011) 1.53
Preclinical toxicity of a geldanamycin analog, 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG), in rats and dogs: potential clinical relevance. Cancer Chemother Pharmacol (2005) 1.53
Akt plays a central role in sarcomagenesis induced by Kaposi's sarcoma herpesvirus-encoded G protein-coupled receptor. Proc Natl Acad Sci U S A (2004) 1.52
Diagnostic markers that distinguish colon and ovarian adenocarcinomas: identification by genomic, proteomic, and tissue array profiling. Cancer Res (2003) 1.51
Inhibition of helicase activity by a small molecule impairs Werner syndrome helicase (WRN) function in the cellular response to DNA damage or replication stress. Proc Natl Acad Sci U S A (2011) 1.45
Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys (2005) 1.44
Mining the National Cancer Institute's tumor-screening database: identification of compounds with similar cellular activities. J Med Chem (2002) 1.43
Detailed DNA methylation profiles of the E-cadherin promoter in the NCI-60 cancer cells. Mol Cancer Ther (2007) 1.42
Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms. J Clin Oncol (2002) 1.40
Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia. Nat Rev Clin Oncol (2012) 1.37
Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies. Eur J Cancer (2009) 1.36
Complex display of putative tumor stem cell markers in the NCI60 tumor cell line panel. Stem Cells (2010) 1.35
Novel small molecule inhibitors of botulinum neurotoxin A metalloprotease activity. Biochem Biophys Res Commun (2003) 1.34
Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models. Cancer Chemother Pharmacol (2005) 1.33
Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells. Mol Cancer (2009) 1.32
Role of the VEGF/VEGFR axis in cancer biology and therapy. Adv Cancer Res (2012) 1.32
Fluorinated 2-(4-amino-3-methylphenyl)benzothiazoles induce CYP1A1 expression, become metabolized, and bind to macromolecules in sensitive human cancer cells. Drug Metab Dispos (2004) 1.32
Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies. Clin Cancer Res (2007) 1.27
Multihistology, target-driven pilot trial of oral topotecan as an inhibitor of hypoxia-inducible factor-1α in advanced solid tumors. Clin Cancer Res (2011) 1.22
Gene expression profiling of alveolar soft-part sarcoma (ASPS). BMC Cancer (2009) 1.20
Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies. Drug Resist Updat (2009) 1.20
Natural products and derivatives as leads to cell cycle pathway targets in cancer chemotherapy. Curr Cancer Drug Targets (2002) 1.20
Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator. Clin Cancer Res (2004) 1.19
SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 2: efficacy evaluations. Cancer Res (2004) 1.19
Differential involvement of vascular endothelial growth factor in the survival of hypoxic colon cancer cells. Cancer Res (2008) 1.18
Ligand-directed surface profiling of human cancer cells with combinatorial peptide libraries. Cancer Res (2006) 1.17
Cell type-specific, topoisomerase II-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation by NSC 644221. Clin Cancer Res (2007) 1.17
Hypoxia potentiates glioma-mediated immunosuppression. PLoS One (2011) 1.17
Determination of MS-275, a novel histone deacetylase inhibitor, in human plasma by liquid chromatography-electrospray mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2004) 1.13
Review of UCN-01 development: a lesson in the importance of clinical pharmacology. J Clin Pharmacol (2005) 1.12
New antitumor imidazo[2,1-b]thiazole guanylhydrazones and analogues. J Med Chem (2008) 1.12
Aryl hydrocarbon receptor activation of an antitumor aminoflavone: basis of selective toxicity for MCF-7 breast tumor cells. Mol Cancer Ther (2004) 1.12
Cellular inhibition of checkpoint kinase 2 (Chk2) and potentiation of camptothecins and radiation by the novel Chk2 inhibitor PV1019 [7-nitro-1H-indole-2-carboxylic acid {4-[1-(guanidinohydrazone)-ethyl]-phenyl}-amide]. J Pharmacol Exp Ther (2009) 1.11
Expression of the vascular endothelial cell protein C receptor in epithelial tumour cells. Eur J Cancer (2002) 1.10
Involvement of reactive oxygen species in adaphostin-induced cytotoxicity in human leukemia cells. Blood (2003) 1.10
Transcriptional regulation of the transforming growth factor beta type II receptor gene by histone acetyltransferase and deacetylase is mediated by NF-Y in human breast cancer cells. J Biol Chem (2001) 1.10
7-hydroxystaurosporine (UCN-01) inhibition of Akt Thr308 but not Ser473 phosphorylation: a basis for decreased insulin-stimulated glucose transport. Clin Cancer Res (2004) 1.10
A high-throughput fluorescence-anisotropy screen that identifies small molecule inhibitors of the DNA binding of B-ZIP transcription factors. Anal Biochem (2005) 1.09
Flavopiridol-related proinflammatory syndrome is associated with induction of interleukin-6. Clin Cancer Res (2003) 1.07
Aminoflavone, a ligand of the aryl hydrocarbon receptor, inhibits HIF-1alpha expression in an AhR-independent fashion. Cancer Res (2010) 1.07
Clinical pharmacology of flavopiridol following a 72-hour continuous infusion. Ann Pharmacother (2003) 1.07
Adaphostin-induced apoptosis in CLL B cells is associated with induction of oxidative stress and exhibits synergy with fludarabine. Blood (2004) 1.06
CpG-containing oligodeoxynucleotide promotes microglial cell uptake of amyloid beta 1-42 peptide by up-regulating the expression of the G-protein- coupled receptor mFPR2. FASEB J (2005) 1.06
Preclinical studies of vorinostat (suberoylanilide hydroxamic acid) combined with cytosine arabinoside and etoposide for treatment of acute leukemias. Clin Cancer Res (2009) 1.05
Perifosine, a novel alkylphospholipid, induces p21(WAF1) expression in squamous carcinoma cells through a p53-independent pathway, leading to loss in cyclin-dependent kinase activity and cell cycle arrest. Cancer Res (2002) 1.05
Application of high-throughput, molecular-targeted screening to anticancer drug discovery. Curr Top Med Chem (2002) 1.05